Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Phase 2
190
about 5.1 years
18+
1 site in FL
What this study is about
This trial is testing whether adding ruxolitinib, a new drug, to radiation therapy and temozolomide improves outcomes in people with newly diagnosed glioblastoma. Participants will be randomly assigned to receive either the standard treatment (radiation and temozolomide) or the standard treatment plus ruxolitinib.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Radiation Therapy
- 2.Take Ruxolitinib
- 3.Take Temozolomide
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ruxolitinib, temozolomide
oral (Oral Tablet), injection, intravenous
Primary: Overall survival (OS) at end of study
Secondary: Duration of response (DOR), Incidence of Adverse Events (AEs), Incidence of Serious Adverse Events (SAEs), Mortality, OS at 12 months, Objective response rate (ORR), PFS at 12 months, Progression-free survival (PFS) at 6 months
radiation
Neurology, Oncology